Translating the Science of Cancer Dormancy to the Clinic.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 09 2021
15 09 2021
Historique:
received:
04
05
2021
revised:
16
06
2021
accepted:
08
07
2021
pubmed:
26
8
2021
medline:
4
1
2022
entrez:
25
8
2021
Statut:
ppublish
Résumé
The paradigm of metastasis has been significantly remodeled by the incorporation of cancer dormancy as a mechanism to explain long-term remission intervals followed by relapse. There is overall consensus on the potential impact of better understanding dormancy. Key cancer-cell autonomous and microenvironmental mechanisms might explain this biology and, in turn, the timing of metastasis. However, the approach and feasibility to apply this biology to clinical trials has been controversial. The discussion here provides insight into how these controversies are being resolved by the development of active clinical trials, thus bringing to reality opportunities to target cancer dormancy.
Identifiants
pubmed: 34429327
pii: 0008-5472.CAN-21-1407
doi: 10.1158/0008-5472.CAN-21-1407
pmc: PMC8562555
mid: NIHMS1725463
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4673-4675Subventions
Organisme : NCI NIH HHS
ID : R01 CA109182
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Nat Cancer. 2020 Jul;1(7):672-680
pubmed: 33681821
Cold Spring Harb Perspect Med. 2020 Apr 1;10(4):
pubmed: 31548220
Cancer Biol Ther. 2007 Sep;6(9):1496-504
pubmed: 17881897
Nat Rev Cancer. 2020 Nov;20(11):681-694
pubmed: 33024261
Nat Rev Cancer. 2020 Jul;20(7):398-411
pubmed: 32488200
Breast Cancer Res. 2018 Oct 16;20(1):120
pubmed: 30322396
Nat Cell Biol. 2019 Feb;21(2):238-250
pubmed: 30664790